vimarsana.com
Latest Breaking News On - Second product candidate - Page 1 : vimarsana.com
Lyra Therapeutics Announces Completion of Enrollment in the
Topline Results Expected in Q4 2023 LYR-220 is Lyra’s Second Product Candidate, Following LYR-210 in Surgically-Naïve CRS patients WATERTOWN,.
United-states
Russia
Ukraine
Richard-nieman
Ellen-cavaleri
Int-forum-allergy-rhinol
Company-or-lyra
Lyra-therapeutics-inc
Nasdaq
Results-expected
Second-product-candidate
Chief-medical-officer
vimarsana © 2020. All Rights Reserved.